Paxton Secures $720M from Drug Manufacturers for their Role in the Catastrophic Opioid Epidemic

Translate to Spanish or other 102 languages!

Attorney General Ken Paxton secured a new opioid settlement worth $720 million with eight drug makers that manufactured opioid pills and worsened the nationwide opioid crisis. In partnership with State Attorneys General across the country, this settlement will allow all local governments to participate through a sign-on period. The State of Texas and its political subdivisions could receive up to $45.5 million. Image for illustration purposes
Attorney General Ken Paxton secured a new opioid settlement worth $720 million with eight drug makers that manufactured opioid pills and worsened the nationwide opioid crisis. In partnership with State Attorneys General across the country, this settlement will allow all local governments to participate through a sign-on period. The State of Texas and its political subdivisions could receive up to $45.5 million. Image for illustration purposes
- Advertisement -

AUSTIN – Attorney General Ken Paxton secured a new opioid settlement worth $720 million with eight drug makers that manufactured opioid pills and worsened the nationwide opioid crisis. In partnership with State Attorneys General across the country, this settlement will allow all local governments to participate through a sign-on period. The State of Texas and its political subdivisions could receive up to $45.5 million. 

“These manufacturers played a role in creating one of the most destructive public health crises our country has ever faced,” said Attorney General Paxton. “These settlements are an important step in holding companies accountable for their reckless greed and the part they had in worsening the opioid epidemic, which has devastated our communities and poisoned countless Texans.” 

The eight defendants and the total amount they will pay in funds to address the opioid crisis as part of the deal are: 

- Advertisement -
  • Mylan (now a part of Viatris): $284,447,916 paid over nine years  
  • Hikma: $95,818,293 paid over one to four years  
  • Amneal: $71,751,010 paid over 10 years  
  • Apotex: $63,682,369 paid in a single year  
  • Indivior: $38,022,450 paid over four years  
  • Sun: $30,992,087 paid over one to four years  
  • Alvogen: $18,680,162 paid in a single year  
  • Zydus: $14,859,220 paid in a single year  

In addition to these abatement payments, the companies have also agreed to injunctive relief. Seven of the companies—not including Indivior—are prohibited from promoting or marketing opioid products, from making or selling any product that contains more than 40 mg of oxycodone per pill, and are required to put in place a monitoring and reporting system for suspicious orders. Indivior, for its part, has agreed to not manufacture or sell opioid products for the next 10 years, but it will be able to continue marketing and selling medications to treat opioid use disorder. 

Including this new settlement, Attorney General Paxton has obtained settlements committing nearly $3.34 billion in funds for Texas from companies that helped fuel the catastrophic opioid crisis.  

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

Celebrate Mom with a Health Check: DHR Health’s “Mammos for Moms” Mammogram Screening Special

In support of women’s health and early detection, DHR Health is delighted to offer the "Mammos for Moms" screening special from now until June 30, 2026. This screening mammogram will provide digital 3D (three dimensional) tomography imaging and radiologist interpretation for only $99. A referral from a physician or other health care provider is required.

Breaking Down the E-Bike Exercise Myth

Mega Doctor News By American Heart Association Anyone who’s sweated their way up...

Some Expectant Mothers Suffer Severe Condition – Not Just “Morning Sickness”

Mothers-to-be suffering severe nausea, vomiting, and weight loss – to the point of being incapacitated – might have a more serious condition than ordinary morning sickness many women experience during pregnancy.

The Future of Stroke Care: How Advanced Imaging Drives Surgical Precision

When a person first exhibits signs of having a stroke, the timing of treatment is critical to restore blood flow to the brain and support recovery.
- Advertisement -